Role of Neoadjuvant Therapy for Esophageal Adenocarcinoma

Surgical Oncology Clinics of North America

Volumn 18, Issue 3, 2009, Pages 533-546

  Ku, Geoffrey Y ^a   Ilson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adenocarcinoma; Cancer; Chemoradiotherapy; Chemotherapy; Combined modality therapy; Esophageal; Gastroesophageal

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; PACLITAXEL; VINBLASTINE;

BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; HISTOPATHOLOGY; HUMAN; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION RESPONSE; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CANCER; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; EVIDENCE-BASED PRACTICE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 66149104733     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2009.03.004     Document Type: Review

References (60)

1. Muller J.M., Erasmi H., Stelzner M., et al. Surgical therapy of oesophageal carcinoma. Br J Surg 77 (1990) 845-857
2. Hulscher J.B., van Sandick J.W., de Boer A.G., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347 (2002) 1662-1669
3. Enzinger P.C., and Mayer R.J. Esophageal cancer. N Engl J Med 349 (2003) 2241-2252
4. Harris D.T., and Mastrangelo M.J. Theory and application of early systemic therapy. Semin Oncol 18 (1991) 493-503
5. Kelsen D.P., Ginsberg R., Pajak T.F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339 (1998) 1979-1984
6. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359 (2002) 1727-1733
7. Allum W., Fogarty P., Stenning S., et al. Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer. [abstract 9]. Proceedings of the Gastrointestinals American Society of Clinical Oncologists (2008)
8. Gebski V., Burmeister B., Smithers B.M., et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8 (2007) 226-234
9. Thirion P., Michiels S., Le Maître A., et al. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. [abstract 4512]. In: J Clin Oncol 25 (2007) 18S
10. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
11. Boige V., Pignon J., Saint-Aubert B., et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. [abstract 4510]. J Clin Oncol 25 (2007) 18S
12. Arnott S.J., Duncan W., Gignoux M., et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev (2005) CD001799
13. Ando N., Iizuka T., Ide H., et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 21 (2003) 4592-4596
14. Ando N., Iizuka T., Kakegawa T., et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 114 (1997) 205-209
15. Pouliquen X., Levard H., Hay J.M., et al. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus: a multicenter randomized trial. French Associations for Surgical Research. Ann Surg 223 (1996) 127-133
16. Armanios M., Xu R., Forastiere A.A., et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol 22 (2004) 4495-4499
17. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
18. Coia L.R., Engstrom P.F., Paul A.R., et al. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 20 (1991) 29-36
19. Valerdi J.J., Tejedor M., Illarramendi J.J., et al. Neoadjuvant chemotherapy and radiotherapy in locally advanced esophagus carcinoma: long-term results. Int J Radiat Oncol Biol Phys 27 (1993) 843-847
20. Berger A.C., Farma J., Scott W.J., et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23 (2005) 4330-4337
21. Makary M.A., Kiernan P.D., Sheridan M.J., et al. Multimodality treatment for esophageal cancer: the role of surgery and neoadjuvant therapy. Am Surg 69 (2003) 693-700
22. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23 (2005) 2310-2317
23. Heath E.I., Burtness B.A., Heitmiller R.F., et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18 (2000) 868-876
24. Forastiere A.A., Orringer M.B., Perez-Tamayo C., et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 11 (1993) 1118-1123
25. Geh J.I. The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer 38 (2002) 300-313
26. Herskovic A., Martz K., al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326 (1992) 1593-1598
27. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281 (1999) 1623-1627
28. Minsky B.D., Pajak T.F., Ginsberg R.J., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20 (2002) 1167-1174
29. Gaspar L.E., Winter K., Kocha W.I., et al. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer 88 (2000) 988-995
30. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337 (1997) 161-167
31. Urba S.G., Orringer M.B., Turrisi A., et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19 (2001) 305-313
32. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
33. Orringer M.B., Marshall B., and Iannettoni M.D. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 230 (1999) 392-400
34. Burmeister B.H., Smithers B.M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6 (2005) 659-668
35. Tepper J., Krasna M.J., Niedzwiecki D., et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26 (2008) 1086-1092
36. Stahl M, Wilke H, Lehmann N, et al. GOCS. Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus [abstract 4530]. In Proceedings of American Society of Clinical Oncology Annual Meeting. Chicago: 2008.
37. Bedenne L., Michel P., Bouche O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25 (2007) 1160-1168
38. Carstens H, Albertsson M, Friesland S, et al. A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer [abstract 4530]. American Society of Clinical Oncology 2007.
39. Adelstein D.J., Rice T.W., Rybicki L.A., et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 18 (2000) 2032-2039
40. Blanke C.D., Choy H., Teng M., et al. Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Semin Radiat Oncol 9 (1999) 43-52
41. Urba S.G., Orringer M.B., Ianettonni M., et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98 (2003) 2177-2183
42. Brenner B., Ilson D.H., Minsky B.D., et al. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 22 (2004) 45-52
43. Safran H., Gaissert H., Akerman P., et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 19 (2001) 1-7
44. van Meerten E., Muller K., Tilanus H.W., et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 94 (2006) 1389-1394
45. Henry L.R., Goldberg M., Scott W., et al. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Ann Surg Oncol 13 (2006) 214-220
46. Meluch A.A., Greco F.A., Gray J.R., et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 9 (2003) 251-260
47. Weiner L.M., Colarusso P., Goldberg M., et al. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Semin Oncol 24 (1997) S19-S95
48. Wright C.D., Wain J.C., Lynch T.J., et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg 114 (1997) 811-815
49. Roof K.S., Coen J., Lynch T.J., et al. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 65 (2006) 1120-1128
50. Ilson D.H., Saltz L., Enzinger P., et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17 (1999) 3270-3275
51. Enzinger P., Mamon H., Choi N., et al. Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. [abstract 35]. Proceedings of the Gastrointestinals American Society of Clinical Oncologists (2004)
52. Ilson D.H., Bains M., Kelsen D.P., et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 21 (2003) 2926-2932
53. Ku G., Bains M., Rizk N., et al. Phase II trial of pre-operative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: PET scan after induction therapy may identify early treatment failure. [abstract 9]. Proceedings of the Gastrointestinals American Society of Clinical Oncologists (2007)
54. Ajani J.A., Winter K., Komaki R., et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 26 28 (2008) 4551-4556
55. 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21 (2003) 428-432
56. Flamen P., Van Cutsem E., Lerut A., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 (2002) 361-368
57. Ott K., Weber W.A., Lordick F., et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24 (2006) 4692-4698
58. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3085
59. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8 (2007) 797-805
60. Lordick F., Ott K., Krause B., et al. Salvage radiochemotherapy in locally advanced gastroesophageal junction tumors that are metabolically resistant to induction chemotherapy: the MUNICON-2 trial. [abstract 104]. Proceedings of the Gastrointestinals American Society of Clinical Oncologists (2008)